Key Issues Biotech and Pharma Companies Must Address to Succeed in Out-Licensing
Pharma and biotech out-licensing and partnering are essential growth drivers for innovative life sciences companies. Yet, despite repeated appearances at partnering conferences, widespread distribution of pitch decks, and months of business development effort, deal outcomes often remain elusive. This persistent disconnect is rarely attributable to the scientific merit of the asset. More often, it reflects an unoptimized outlicensing process itself, ranging from knowledge gaps to execution shortfalls. Understanding these key issues is the first step toward unlocking greater deal velocity and value maximization.
1. Fragmented Intelligence on Potential Partners
The biopharma partnering landscape evolves rapidly. Pipeline priorities shift, and therapeutic focus areas are redefined. However, most out-licensing seeking pharma and biotech companies naively target the usual big pharma for licensing and partnering. New entrants emerge, while others exit the stage. Unfortunately, most early-stage innovators lack the dedicated market intelligence capabilities to track these movements in real-time. Consequently, outreach is often misdirected, focused on the wrong targets or missing viable, high-fit prospects entirely. A static view of the partnering ecosystem undermines an asset’s visibility where it matters most.
2. Organizational Complexity Within Target Companies
Partnering decisions are rarely the remit of a single individual. More often, they reflect a consensus between scientific, commercial, clinical, and legal stakeholders, each with unique perspectives, priorities, and constraints. Yet many outlicensing campaigns engage with only one function (typically business development) and hope for a favourable outcome. Without a multi-pronged strategy that anticipates and addresses the needs of several decision influencers, discussions don’t progress or quietly fade.
3. Absence of High-Quality Contact Channels
Even when a target company is well-chosen, the inability to reach the right individuals can derail momentum. Outreach often defaults to generic email addresses, outdated directories, or passive networking. These channels yield limited engagement. For high-value deals to materialize, companies must be able to connect directly with empowered stakeholders, ideally through warm introductions or trusted intermediaries.
4. Biotech out-licensing is Overdependent on Conferences
Major conferences play a valuable role in generating leads and sparking interest. However, reliance on these episodic touchpoints creates timing misalignments and opportunity gaps. A company prepared to license an asset in March may find its pipeline of partner conversations goes dormant until June’s industry events. Furthermore, the crowded nature of these forums makes it difficult to secure meaningful mindshare, especially for emerging players, despite engaging with multiple potential partners.
5. Treating Out-Licensing as a Side-on Task
Approaching out-licensing as an ancillary business activity, rather than as a focused, project-driven initiative, limits success. Effective out-licensing requires dedicated resources, clear objectives, and proactive project management. When out-licensing is treated as an afterthought or a side responsibility, opportunities are missed, timelines are extended, and the likelihood of securing a favorable deal diminishes.
6. Underpowered Execution of Biopharma Outlicensing Strategy
In an effort to manage costs, many emerging biotech and pharma companies turn to part-time or fractional business development officers to lead their outlicensing initiatives. While these professionals often bring valuable experience and industry insight, they are seldom provided with a full suite of resources necessary for running a comprehensive outlicensing program.
7. Insufficient Preparation of Licensing Assets
Too many companies initiate outreach with underdeveloped materials, generic decks, non-customized slide packs, or one-size-fits-all messaging. Prospective licensees expect clarity on the mechanism of action, differentiation, market positioning, clinical path, and route to markets. The absence of tailored collateral shows a lack of intent and slows the dialogue between the licensor and potential licensees. Proper preparation is vital before executing an outreach strategy and is worth reviewing in our comprehensive out-licensing guide.
8. Lack of Internal Alignment on Out-licensing Deal
Misalignment within the innovator company, whether between founders, investors, or functional teams, can delay or dilute out-licensing outcomes. Internal consensus is critical across several dimensions, including licensing objectives, target geographies, and execution approaches. In addition, companies must be prepared to absorb and act on market feedback from prospective licensees, using it to refine both positioning and outreach strategy.
Each of these hurdles represents a drag on deal velocity—and, by extension, on the value of the asset being licensed. For a practical, step-by-step guide to accelerating your outlicensing efforts, from identifying high-fit partners to optimizing outreach, refer to our companion piece on proven strategies that biotech and pharma companies can adopt to overcome these challenges and expedite the partnering process.
BiopharmaVantage provides strategic and execution support to emerging biotech and pharmaceutical companies seeking to unlock the full value of their assets through effective licensing and partnering. To learn more about how we can support your out-licensing objectives, please contact us.